Purpose: A variety of dose/fractionation schemes are used for adjuvant radiotherapy (RT) in node positive (Stage III) melanoma. A prospective randomized study of adjuvant nodal radiation for high-risk Stage III melanoma used 2.4 Gy x 20 fractions in four weeks. The largest retrospective series to date used a hypofractionated scheme of 6 Gy x 5 fractions over 2.5 weeks. No randomized comparison of these has been reported. At our institution, either fractionation is used based on physician and patient preference. We sought to compare clinical outcomes using hypofractionated and conventional radiotherapy for node positive melanoma. Methods and Materials: Patients who received adjuvant radiation for node positive melanoma between 2009 and 2014 were included. Kaplan-Meier estimates of overall survival (OS) and 95% confidence intervals (CI) were obtained. Logistic regression was used to explore the association between patient, tumour and treatment factors for the outcomes of these patients.
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Peter Mathen 1 , Brock Debenham 2 , Jon-Paul Voroney 1 , Robyn Banerjee 1 1 University of Calgary, Calgary, AB 2 University of Alberta, Edmonton, AB Purpose: Stage III cutaneous melanoma incorporates a heterogeneous patient group with node positive disease. Adjuvant radiotherapy decreases regional recurrence but its use is sporadic, in part due to a high competing risk of distant failure. This study aimed to assess our institutional practice patterns, evaluate clinical outcomes post radiotherapy, and identify risk factors for distant metastases in Stage III melanoma patients. Methods and Materials: Patients who received adjuvant radiation for node positive melanoma between 2009 and 2014 were included. Kaplan-Meier estimates of overall survival (OS) and 95% confidence intervals (CI) were obtained. Logistic regression was used to explore the association between patient, tumour and treatment factors for the outcomes of these patients.
Results: Forty-one patients were analyzed. Median follow up was two years. Sixty-one percent presented with palpable nodal disease. Sixty-six percent had a sentinel lymph node procedure prior to completion nodal dissection. Patients had an average of three involved lymph nodes and 23 total lymph nodes removed. Extracapsular extension was present in 51% of patients. Sixty-one percent of patients received hypofractionated radiotherapy (30 Gy/5 fractions or 36 Gy/6 fractions over 2.5-3 weeks) versus 39% who received conventional fractionation (typically 48 Gy/20 fractions). Regional radiation targets included the axilla (39%), head and neck (32%) and groin (29%). At two years, regional control was 82% and distant control was 46%. Median overall survival was 3.7 years. All patients who experienced a regional failure post-RT developed distant metastases and died of melanoma. All patients who were free of distant failure had regional control. Development of distant metastases was strongly associated with extracapsular extension (HR 4.0, 95% CI 1.8-8.7, p < 0.0001). T-stage, N-stage, RT dose, neurotropism, nodal size, location and number involved were not associated with regional or distant control. Conclusions: Patients who receive adjuvant radiotherapy for node positive melanoma have high rates of regional control but are prone to distant failure. Regional failure is a harbinger of distant disease. Extracapsular extension also predicts distant failure in this population. benefits has changed the landscape of care, and may impact the demand for and provision of palliative radiation to bone (PRTB) in this population. The purpose is to describe the use of PRTB in patients who died of prostate in British Columbia between 2003 and 2015. Methods and Materials: All patients that died of prostate cancer in the time period were identified from a population-based provincial cancer registry. Exclusion criteria included: other sites of cancer diagnosis, lack of adenocarcinoma histology, RT to nonbone sites or of non-palliative intent. Patient and treatment characteristics were analyzed using SAS. PRTB use for the first and last courses was calculated by year of death, overall, and by region. Survival was calculated for the following: from first course of PRTB to death, from last course of PRTB to death, and by treatment year. To assess the adequacy of provision of PRTB in this population, the geographical distribution of the incidence of prostate cancer was compared with the treatment frequency across the province. Results: Out of 23,260 prostate cancer patients who died between 2003 and 2015, 5701 had prostate adenocarcinoma as their only primary cancer diagnosis. The median age at the time of death was 81 and median survival after diagnosis was 5.2 years. Utilization of PRTB prior to death was 38.6% (2203 patients), with a trend to increase overtime from 29% in 2003, to 44% in 2015. Multiple courses of PRTB were frequent, with patients receiving two, three, four or more courses of PRTB in 25%, 13%, and 14% of cases respectively. Survival after first course of PRTB to prostate cancer death was 38.6% at one year, and 2.3% at five years, and a median of 8.5 months. Median survival after first course of PRTB increased slightly over the study years for those dying of prostate cancer from 8.2 months in 2003-5 to 9.4 months in 2013-15 (p = 0.04). For last course of PRTB, 2% were treatment within the last four weeks of their life. Use of PRTB varied with region and was lower in some rural areas.
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